Page results
-
Everyone is invited to share their views on the future of maternity, neonatal and children’s surgical services in North Central London as a 14-week public consultation launches today.
-
A world-first treatment for Creutzfeldt-Jakob disease (CJD) has shown “very encouraging” early results following its use in six patients at University College London Hospitals (UCLH) NHS Foundation Trust.
-
Robot-assisted surgery used to perform bladder cancer removal and reconstruction enables patients to recover far more quickly and spend significantly less time in hospital, concludes a trial led by UCLH, UCL and the University of Sheffield.
-
Patients waiting for an appointment or worrying about a diagnosis will be inspired by a major new photography exhibition at the Royal National ENT and Eastman Dental Hospitals to highlight the achievements of deaf people.
-
Bladder cancer is where a growth of abnormal tissue, known as a tumour, develops in the bladder lining. In some cases, the tumour spreads into the surrounding areas.
-
This page explains what a low-phosphate diet is. It also provides information about foods you can eat and foods to avoid when taking a medicine called futibatinib.
-
This page is for patients with obesity who are waiting for scheduled surgery.
-
A national study with initial results shows steroid dexamethasone may substantially reduce mortality in severely ill Covid-19 patients.
-
Pfizer Limited, in agreement with the Medicines Healthcare products Regulatory Agency (MHRA), has withdrawn the product, while a review of the benefits and risks is carried out.
-
Mr George Attilakos is a consultant in obstetrics and fetal medicine and the clinical lead for obstetrics at UCLH. Alongside managing normal pregnancies, Mr Attilakos has a special interest in the management of multiple pregnancies and high-risk pregnancies, as well as expertise in fetal medicine and fetal surgery, including in-utero treatment for congenital diaphragmatic hernia, spina bifida and twin-to-twin transfusion syndrome.
File results
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0509 - Structure chart for Estates and Facilities
-
FOI/2024/0513 - Robotic platforms for surgery costs/ contract
-
FOI/2024/0512 - Patient harm and the cost 2020-2023
-
FOI/2024/0511 - Radiotherapy treatment planning system/artificial intelligence (AI)/ costs
-
FOI/2024/0514 - Viscosupplementation injections/ spend
-
FOI/2024/0506 - Permanent/ fixed-term/ international recruitment